Laboratory Kickbacks: What the Referral Payment Actually Buys

Laboratory kickbacks are payments or benefits used to buy laboratory referrals, whether the value arrives as cash, free staff, subsidized software or an investment distribution. The invoice may say consulting. The sales team may call it an opportunity for the practice. For someone inside the lab, the revealing question is what the recipient had to send back: specimens, test orders, patients or revenue. The people processing the payments and the people processing the samples may each see only half of the arrangement.

From the Test Order to the Referral Payment

A doctor orders a test, a laboratory performs it, and a payer receives the bill. The referral payment runs back toward whoever sent the business.

Medicare’s ordering and documentation rules require the treating practitioner’s record to show why the test was needed. The laboratory’s bill must accurately reflect the information it received. The practitioner uses the result to manage the patient’s medical problem.

That division matters inside the business. A requisition identifies the requested tests. The result records the laboratory’s work. The claim identifies what the payer was asked to fund. The compensation records show who benefited from getting that business to that laboratory.

A hospital or marketing company can add another layer. The entity on the bill may differ from the laboratory that performed the test, while a separate company pays the physician. Following only the laboratory’s checks can leave the referral payment out of view.

Do Doctors Get Kickbacks for Ordering Tests?

Yes. Laboratory cases have involved payments to doctors for sending tests, including fees described as processing, consulting and investment returns. Some arrangements have produced jury findings, as well as civil settlements.

Health Diagnostic Laboratory and Singulex agreed to settle allegations in 2015 involving processing and handling payments of $10 to $17 per referral. The government alleged that those payments and routine patient-payment waivers induced referrals for medically unnecessary blood tests billed to federal healthcare programs.

A separate trial produced a jury verdict against Health Diagnostic Laboratory’s former chief executive and two BlueWave executives. The court’s account of the evidence describes payments to physicians for drawing and processing blood samples in violation of the Anti-Kickback Statute. The sales arrangement paid BlueWave Healthcare Consultants a share of laboratory revenue tied to ordered tests.

The Different Ways a Lab Can Pay for Referrals

The benefit can reach a physician personally, reduce a practice’s expenses or reward the person recruiting the business. Each form leaves a different comparison between the promised service, the work performed and the referrals expected in return.

Processing and Handling Fees

A processing fee puts a price on each specimen moving through the practice. The useful details are who drew the blood, who handled and shipped it, what work the practice actually supplied, and how the laboratory calculated the payment.

The Health Diagnostic Laboratory allegations show why a small payment per referral deserves attention. It attaches the practice’s income to the same act that generates a laboratory claim. In the government’s account, the incentive also encouraged unnecessary testing. The fee schedule, specimen records and sales pitch explain different parts of that relationship.

Consulting and Medical Director Fees

A monthly payment can buy continuing referrals under the name of an ongoing professional role. NEXT Molecular Analytics agreed to a settlement in December 2025 to resolve allegations that it paid doctors kickbacks disguised as consulting and medical director fees. The government alleged that NEXT billed Medicare, Medicaid and TRICARE for tests despite knowing about the payments.

The claimed job needs to be compared with the job someone actually did. What advice reached the laboratory, and who decided the physician’s compensation?

The government’s complaint announcement concerning True Health Diagnostics supplied a particularly clear example: it alleged that a top-referring doctor received monthly consulting fees for participating in an advisory board that did not exist. A monthly paycheck for a seat on an allegedly nonexistent board.

Marketer Commissions

Marketer payments can reward the intermediary who arranges the order. The NEXT settlement also addressed alleged commissions to independent contractors based on the volume and value of laboratory referrals.

We examine what triggered the payment, who could influence it, and what the marketer promised the practice. The commission formula can explain why a particular doctor, payer or test became a sales priority.

Rent, Equipment, Staff and Supplies

A laboratory can transfer value by paying too much for something or by supplying something the practice would otherwise pay for.

BioReference settled allegations concerning above-market office rent in July 2022. The rented space housed patient service centers where blood samples were taken. BioReference admitted inaccurately measuring its exclusive space and including a disproportionate share of common areas in certain leases. It also admitted that internal audits showed payments above fair market value.

Referral analyses also entered BioReference’s decisions about opening, keeping or closing those locations. The company was measuring the business a location would bring in while overstating the space it rented.

Labtech’s January 2026 civil settlement covered alleged false descriptions of rent, phlebotomy and toxicology services, including falsified square footage and hours. The government also alleged an inflated purchase price for used laboratory equipment and free services and supplies for a pain practice in return for drug confirmation testing referrals. An equipment purchase and a staff subsidy could serve the same sales objective.

Electronic Health Records and Software Subsidies

Software can carry a referral payment into the everyday work of a physician’s office. In its 2020 settlement admissions, BioReference acknowledged conditioning software payments on whether a practice would generate revenue equal to three times the software’s value.

The company’s admitted email traffic made the purpose plain:

The comparison was between the software expense and the laboratory business expected back. A technology budget had become a referral calculation.

Miraca Life Sciences’ settlement over electronic-health-record subsidies addressed alleged free or discounted technology consulting as well. In that arrangement, the value included work performed for the practice, alongside the software subsidy.

Research Payments and In-Office Technicians

A research arrangement can supply both a reason to pay the doctor and personnel inside the practice. In the Primex Clinical Laboratories and DNA Stat case, the government alleged that payments presented as compensation for clinical study data actually paid physicians for referrals. It also alleged that the defendants provided in-office medical technicians.

What did the study require the physician to contribute, and what actually caused a payment to become due? The study protocol, data delivered and technician’s daily work help answer that. Calling the recipient a researcher leaves the same physician in control of the orders generating laboratory revenue.

Copayment Waivers

Laboratory copayment waivers can make the referral easier to sell to a patient and easier for the practice to keep sending. The government alleged routine waivers alongside the physician payments in the cardiovascular-testing cases.

Where a patient owes part of the bill, that charge can become part of the sales pitch.

We examine the patient’s actual obligation, the laboratory’s collection policy and what the sales team told the practice. Who promised that patients would never pay, and what referrals did that promise bring in?

Telemedicine and Genetic Testing Orders

Laboratory kickbacks can buy a doctor’s signature through a telemedicine company. In its account of the Operation Double Helix criminal charges, the Justice Department alleged that cancer genetic testing laboratories paid kickbacks for Medicare patient referrals through telemedicine companies. The charges alleged that doctors prescribed tests without patient interaction or after only a brief telephone conversation. Test results often never reached the patients or were worthless to their treating doctors.

The order arrived with a physician’s signature. The allegation was that the laboratory had bought the route to that signature.

MSOs Can Move the Money Through a Hospital

A management service organization can carry money from laboratory testing back to the doctor who ordered it. In the True Health Diagnostics, Boston Heart Diagnostics and Little River Healthcare allegations, the government described hospitals paying part of their laboratory profits to recruiters, who then paid referring physicians through MSOs.

The government’s account of the arrangement alleged that the payments were dressed as investment returns but depended on referrals. Boston Heart and True Health performed the testing. Little River allegedly billed tests as hospital outpatient services to increase reimbursement. Laboratory sales employees allegedly used the physician payments to increase their own bonuses and commissions.

The arrangement gave several participants a reason to keep the orders coming. The hospital received testing revenue, the recruiter received a share, the physician received a distribution and the sales employee benefited from the resulting volume.

A separate whistleblower complaint against Boston Heart quoted a representative explaining a third-party payment arrangement:

The passage shows why the intermediary’s records matter. The laboratory’s payment may name a company while the benefit ultimately reaches the referring practice.

In June 2026 settlements involving Boston Heart’s former leadership, the Justice Department alleged that executives expanded a Texas hospital arrangement despite an internal recommendation to stop it. The internal warning showed what management had been told before it expanded the arrangement.

How the Anti-Kickback Statute, Stark and EKRA Reach Lab Referrals

The Anti-Kickback Statute, Stark Law and EKRA reach different parts of laboratory referral arrangements. The payer, recipient, financial relationship and reason for the payment determine which questions need answering.

The Anti-Kickback Statute

The Anti-Kickback Statute targets deliberate exchanges of money or other benefits for referrals that federal health care programs pay for. The benefit can pass through another company or arrive as services instead of cash.

We examine the actual duties, compensation and referral relationship with laboratory fraud whistleblower lawyers. The contract’s title is only the beginning of that examination.

Stark and Physician Financial Relationships

Stark addresses physicians referring lab tests to a business they own or that pays them. The physician’s ownership interest, lease or compensation agreement identifies the financial relationship.

The BioReference rent case shows the connection: payments for the physician’s office space and bills for that physician’s referrals came under scrutiny together.

EKRA and Private Insurance

The Eliminating Kickbacks in Recovery Act, commonly called EKRA, reaches laboratory referral payments involving public or private health plans.

We examine how sales pay changes with referrals, tests and health-plan revenue, including when the contract calls someone an employee.

What Evidence Is Needed to Prove Fraud?

For a False Claims Act case, we connect the referral arrangement to claims for government money and the participants’ knowledge. The payment, the resulting tests and the claims each need evidence.

The strongest account connects the promised benefit to the referral, the test and the claim. People in different parts of the business can explain where those records diverge.

A laboratory salesperson may know what the practice was offered and how the commission was calculated. An accounts payable employee may understand why a consulting invoice changed with referral volume. A practice employee may know what a laboratory-paid technician actually did each day. We connect that firsthand knowledge to the contracts, invoices, work records and communications.

The clinical and billing records supply the other side: the original order, selected tests, specimen and result, performing laboratory, billed service and payer. They allow us to examine whether the work the laboratory billed followed the order and whether the physician’s patient record supported it.

Laboratory design decisions also matter. Model Plan Helps Laboratories Fight Fraud, published in Laboratory Medicine in 1997, describes uniform requisitions, disclosure of profile components and monitoring of standing orders. Its account puts the laboratory’s test offerings and ordering forms alongside the physician’s clinical decision.

That adds a useful question to a payment inquiry: what exactly did a referral authorize? A standing order or customized profile can determine which tests follow the specimen. The original selection and the laboratory’s instructions help explain what business the payment generated.

The Clinical Question Behind the Test Volume

A referral payment can reward test volume while the patient’s reason for testing gets lost. The Medicare ordering rule ties diagnostic testing to the treating practitioner’s use of the result.

Ethical Perspectives on Urine Drug Screening for Pain Physicians, published in Pain Physician in 2014, explains that even a properly collected urine specimen can yield a result that is difficult to interpret. Monitoring prescribed medication requires the clinician to understand what the result means for that patient.

For the referral-payment inquiry, that means asking how the clinician used the result, alongside who received money when the test was ordered. The patient record explains the clinical purpose. The compensation records explain the financial incentive. When payments buy referrals for unnecessary testing, patients get tests they do not need and taxpayers get the bill. Honest laboratories lose orders to competitors willing to pay for them.

Laboratory Kickbacks and Whistleblower Rewards

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. Employees who understand the payment arrangement can connect a laboratory’s sales promises with its claims for government reimbursement.

The Justice Department announced a $1.36 million whistleblower award from Labtech’s civil settlement. NEXT and the cardiovascular-testing laboratories also settled allegations brought in whistleblower cases.

When You Know What the Payment Bought

If you work in a laboratory, physician practice or marketing business and know how referrals were bought, speak with our whistleblower experts about the arrangement. We work with you to build your strongest case around the money, the orders and the decisions behind them, and bring in laboratory fraud whistleblower lawyers who understand referral compensation. We stay beside you from that first account through the case.